HC Wainwright Forecasts Higher Earnings for vTv Therapeutics

Key Points

• HC Wainwright raised several near‑term EPS estimates (Q2 2026 to ($0.64), FY2026 to ($1.03)) and reiterated a Buy rating with a $47 price target, but materially cut long‑range EPS forecasts for FY2028–FY2030, signaling stronger near‑term visibility but increased long‑term skepticism.
• vTv beat the quarter—EPS of ($0.58) versus consensus ($1.09)—and trades around $33.71 (market cap ≈ $132.8M), with an average analyst view of "Moderate Buy" (average price target ~$53) and recent institutional buying activity.

vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) - Investment analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for vTv Therapeutics in a report released on Wednesday, March 11th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will earn ($0.64) per share for the quarter, up from their prior estimate of ($0.70). HC Wainwright has a "Buy" rating and a $47.00 price target on the stock. HC Wainwright also issued estimates for vTv Therapeutics' Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($3.33) EPS, FY2028 earnings at ($3.20) EPS, FY2029 earnings at ($3.21) EPS and FY2030 earnings at ($3.25) EPS.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last posted its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.51. The business had revenue of ($0.02) million for the quarter.

A number of other analysts have also issued reports on the stock. TD Cowen began coverage on shares of vTv Therapeutics in a research note on Monday, January 5th. They issued a "buy" rating for the company. BTIG Research reiterated a "buy" rating and set a $49.00 price objective on shares of vTv Therapeutics in a research note on Wednesday. Weiss Ratings reissued a "sell (d-)" rating on shares of vTv Therapeutics in a report on Monday, December 29th. Evercore started coverage on shares of vTv Therapeutics in a research report on Thursday. They issued an "outperform" rating and a $44.00 target price for the company. Finally, Roth Mkm initiated coverage on shares of vTv Therapeutics in a research note on Thursday, January 22nd. They issued a "buy" rating and a $58.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $53.00.

vTv Therapeutics Trading Down 4.0%

vTv Therapeutics stock opened at $33.71 on Friday. The stock has a market cap of $132.82 million, a P/E ratio of -10.06 and a beta of 0.44. The stock has a 50 day moving average of $36.06 and a 200-day moving average of $29.29. vTv Therapeutics has a 52 week low of $14.00 and a 52 week high of $44.00.

Institutional Trading of vTv Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. bought a new position in shares of vTv Therapeutics in the 4th quarter worth about $221,000. Geode Capital Management LLC raised its stake in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after acquiring an additional 12,896 shares during the period. 683 Capital Management LLC bought a new position in vTv Therapeutics in the fourth quarter worth about $731,000. Finally, Baker BROS. Advisors LP boosted its stake in vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company's stock valued at $3,463,000 after acquiring an additional 51,000 shares during the period. Institutional investors own 17.51% of the company's stock.

More vTv Therapeutics News

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: HC Wainwright raised several near‑term estimates and reiterated a Buy rating with a $47 price target — upgrades include Q1–Q4 2026 and FY2026 EPS forecasts (e.g., FY2026 raised to ($1.03) from ($1.28)) and an improved FY2027 estimate. This suggests the analyst sees stronger near‑term performance or clearer visibility into the business. HC Wainwright analyst note (summary)
• Neutral Sentiment: vTv is expected to announce upcoming earnings (projected release/announcement date reported), and the company recently issued its fourth‑quarter and full‑year 2025 results with a corporate update — these events can add volatility but are information‑driven rather than directionally decisive until details are parsed. Projected Earnings Announcement 4Q & FY2025 Results and Corporate Update
• Negative Sentiment: HC Wainwright materially lowered long‑term EPS forecasts — FY2028, FY2029 and FY2030 estimates were cut (e.g., FY2030 moved to ($3.25) from ($1.67); FY2029 to ($3.21) from ($2.25)). Those deeper long‑range cuts signal increased skepticism about sustainable profitability or longer‑term growth, which can weigh on valuation and investor sentiment despite near‑term upgrades. HC Wainwright analyst note (summary)

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.